Cancer Vaccines Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Cancer vaccines are a distinct therapeutic class within oncology that aims to prevent or treat malignancies by stimulating antigen-specific immune responses, and they are split between preventive products such as HPV and hepatitis B vaccines and therapeutic products targeting tumor-associated antigens. The market is currently worth approximately $11.0 billion in 2025 and is projected to compound at roughly 11.5% per year through the end of the decade. Demand is broadening beyond a handful of approved preventive products as personalized neoantigen vaccines and mRNA-based candidates move through late-stage development.

• •Estimated 2025 market value of about $11.0 billion with an 11.5% CAGR through the late 2020s
• •Preventive vaccines (HPV, hepatitis B) still account for the majority of current revenue
• •Therapeutic vaccines remain a smaller but faster-growing share of the market

Rising global cancer incidence and screening-driven diagnosis rates are expanding the eligible patient population for both preventive and therapeutic vaccines. Advances in genomics, next-generation sequencing, and bioinformatics have made rapid identification of tumor-specific neoantigens feasible, enabling personalized vaccine development at scale. The success of mRNA vaccine technology during the COVID-19 pandemic has accelerated investment in mRNA oncology platforms, while regulatory agencies have begun offering accelerated review pathways for personalized cancer immunotherapies.

• •Growing global cancer burden increases demand for preventive and therapeutic vaccines
• •mRNA platform maturation has shortened development timelines and reduced manufacturing costs
• •Faster genomic sequencing is enabling personalized neoantigen vaccine design within clinically relevant windows

The market is segmented by vaccine type into preventive and therapeutic vaccines, by technology into recombinant, mRNA, dendritic cell, viral vector, and others, and by indication into melanoma, cervical, prostate, lung, colorectal, and additional tumor types. North America leads in revenue share, supported by advanced healthcare infrastructure, high per-capita cancer spending, and a concentration of biotech R&D activity. Asia-Pacific is the fastest-growing region, driven by expanding immunization programs, increasing cancer awareness, and rising healthcare investment in China, Japan, and India.

• •Therapeutic vaccines, particularly mRNA and dendritic cell platforms, are the fastest-growing segment
• •North America holds the largest revenue share; Asia-Pacific is the fastest-growing region
• •HPV-related cancers (cervical, head and neck) remain the leading indication for preventive vaccines

What are the recent trends and outlook?

The most defining trend is the move toward personalized cancer vaccines, where a patient's tumor is sequenced and a custom multi-epitope vaccine is manufactured in weeks, with several candidates reporting positive Phase II readouts in melanoma and other solid tumors. Combination regimens pairing cancer vaccines with immune checkpoint inhibitors are also being tested extensively to convert "cold" tumors into "hot" ones and improve response rates. Looking ahead, the market is expected to more than double by the early 2030s, though the trajectory will depend on the outcome of pivotal trials, reimbursement decisions, and the scalability of individualized manufacturing.

• •Personalized neoantigen vaccines are advancing through mid- and late-stage clinical trials
• •Combinations with checkpoint inhibitors are a major focus of ongoing development
• •Long-range forecasts project the market to surpass $15 billion by the early 2030s and approach $30 billion by mid-2030s